The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment

CNS Drugs
Ceri J Phillips

Abstract

Multiple sclerosis (MS) is one of the most common causes of neurological disability in young and middle-aged adults. The full economic cost of MS is substantial given that MS patients experience a major perturbation in their daily activities and the disease affects mainly young people who are obliged to restrict their levels of economic activity, either temporarily or permanently. A positive relationship exists between the direct and indirect costs of MS and its severity. Cost variations between countries exist because of differences in the costs of inpatient care, the number of ambulatory visits, drug usage and the extent and type of informal care. The development and availability of new agents has been accompanied by an increased optimism that treatment regimens for MS would be more effective. However, doubts have been expressed about the effectiveness of these treatments, which have compounded the problems associated with estimating the relative cost effectiveness of such interventions. In addition, variations in the utility scores associated with disease categories, the impact of relapses and the resulting utility losses, plus the speed of disease progression have all contributed to the difficulty of estimating the quality-...Continue Reading

References

Jan 1, 1991·Journal of Neurology, Neurosurgery, and Psychiatry·M H RobertsA J Spackman
Aug 1, 1971·European Journal of Immunology·D TeitelbaumM Sela
Oct 15, 1994·Lancet·D E Goodkin
Jan 1, 1994·Neuroepidemiology·G Dean
Jan 1, 1994·Neurology·C J MumfordD A Compston
Apr 1, 1993·Journal of Clinical Pharmacy and Therapeutics·D A Francis
Feb 1, 1993·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·A D Sadovnick, G C Ebers
Jan 1, 1996·Rehabilitation Nursing : the Official Journal of the Association of Rehabilitation Nurses·R J GregoryS Firth
Jan 1, 1995·Duodecim; lääketieteellinen aikakauskirja·M PaneliusJ Ruutiainen
Apr 1, 1996·Brain : a Journal of Neurology·N P RobertsonD A Compston
May 1, 1997·Acta Neurologica Scandinavica·C V AscheP C Coyte
Apr 9, 1998·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
May 14, 1998·Canadian Journal of Applied Physiology = Revue Canadienne De Physiologie Appliquée·R Steadward
Oct 15, 1998·Journal of Neurology, Neurosurgery, and Psychiatry·N MurphyJ L Mérot
Nov 7, 1998·Drugs·B W van OostenC H Polman
Nov 20, 1998·Lancet·D E Goodkin
Dec 5, 1998·Multiple Sclerosis : Clinical and Laboratory Research·K Whetten-GoldsteinE D Kulas
Feb 7, 1996·PharmacoEconomics·M Malone, B Lomaestro
Feb 6, 1997·PharmacoEconomics·K H Tolley, D K Whynes
Jan 25, 2000·Journal of Neurology, Neurosurgery, and Psychiatry·D ParkinD Bates
Apr 25, 2000·Drugs·B Weinstock-Guttman, L D Jacobs
Sep 28, 2000·The New England Journal of Medicine·J H NoseworthyB G Weinshenker
Sep 30, 2000·PharmacoEconomics·M Kendrick, K I Johnson
Oct 12, 2000·International Journal of Technology Assessment in Health Care·M G BrownC Skedgel
Oct 12, 2000·International Journal of Technology Assessment in Health Care·G KobeltB Jönsson
Aug 18, 2001·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·F HenrikssonB Jönsson
Jan 24, 2002·Neurology·Roger P Simon, Joseph S Beckman
Mar 5, 2002·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Bruno Detournay
Mar 5, 2002·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Mark J C Nuijten, John Hutton
Mar 29, 2002·Health Economics·Bernie J O'BrienLisa A Faulkner

❮ Previous
Next ❯

Citations

May 16, 2009·Advances in Therapy·Jane Castelli-HaleyKenneth P Johnson
Oct 9, 2007·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Robert A Bermel, Richard A Rudick
Apr 17, 2002·Lancet·Alastair Compston, Alasdair Coles
Jun 10, 2011·The Journal of Infectious Diseases·Jiunn-Horng KangHerng-Ching Lin
Jan 1, 2009·ClinicoEconomics and Outcomes Research : CEOR·Ceri J Phillips, Ioan Humphreys
May 3, 2013·Applied Health Economics and Health Policy·Annie HawtonColin Green
Nov 19, 2011·Multiple Sclerosis International·Mona Alkhawajah, Joel Oger
Jan 3, 2016·Preventive Medicine·Chia-Chun TsengJeng-Hsien Yen
Feb 1, 2008·Expert Review of Pharmacoeconomics & Outcomes Research·Trygve Holmoy, Elisabeth Gulowsen Celius
Oct 1, 2004·Expert Review of Pharmacoeconomics & Outcomes Research·Jeffrey S Hoch
May 9, 2009·Current Medical Research and Opinion·Richard A BrookArthur K Melkonian
Feb 19, 2016·Neurology·Piyameth DilokthornsakulJonathan D Campbell
Apr 17, 2015·Multiple Sclerosis and Related Disorders·Jonathan D CampbellKavita Nair
Aug 24, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Martin RomeroAristides Duque
Oct 19, 2016·Current Medical Research and Opinion·Aseel Bin SawadFatema Turkistani
Oct 20, 2012·American Journal of Preventive Medicine·Gery P GuyLisa C Richardson
Jul 15, 2016·PloS One·Olivia ErnstssonAnders Norlund
Oct 4, 2011·Multiple Sclerosis : Clinical and Laboratory Research·J Blahova DusankovaE Havrdova
Jan 26, 2017·Journal of Comparative Effectiveness Research·Aseel Bin SawadFatema Turkistani
Jan 1, 2012·Journal of Central Nervous System Disease·Oscar Fernández
Jan 9, 2019·Journal of Clinical Neurology·Petros PetrikisSotirios Giannopoulos
Sep 8, 2009·Applied Health Economics and Health Policy·Stephanie R EarnshawKenneth Johnson
Oct 23, 2018·Management Science·Diana M NegoescuDan A Iancu

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved